Treatment of BRAF-Mutant Melanoma:The Role of Vemurafenib and OtherTherapiesJANG, S; ATKINS, M. B.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 1, pp 24-31, issn 0009-9236, 8 p.Article

PD-L1 expression in nonclear-cell renal cell carcinomaCHOUEIRI, T. K; FAY, A. P; STANTON, M. L et al.Annals of oncology. 2014, Vol 25, Num 11, pp 2178-2184, issn 0923-7534, 7 p.Article

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsWANG, X; ZHANG, L; BHATT, R. S et al.British journal of cancer. 2013, Vol 108, Num 2, pp 319-326, issn 0007-0920, 8 p.Article

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. CommentaryFALLICK, M. L; MCDERMOTT, D. F; LAROCK, D et al.The Journal of urology. 1997, Vol 158, Num 5, pp 1691-1695, issn 0022-5347Article

Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppressin of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimeraTILG, H; SHAPIRO, L; ATKINS, M. B et al.The Journal of immunology (1950). 1993, Vol 151, Num 6, pp 3299-3307, issn 0022-1767Article

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; HAWKINS, M. J et al.Journal of clinical oncology. 1992, Vol 10, Num 2, pp 275-281, issn 0732-183XArticle

Chest roentgenographic abnormalities in IL-2 recipients : incidence and correlation with clinical parametersVOGELZANG, P. J; BLOOM, S. M; MIER, J. W et al.Chest. 1992, Vol 101, Num 3, pp 746-752, issn 0012-3692Article

Leukotriene C₄ uses a probenecid-sensitive export carrier that does not recognized leukotriene B₄LAM, B. K; KONGYI XU; ATKINS, M. B et al.Proceedings of the National Academy of Sciences of the United States of America. 1992, Vol 89, Num 23, pp 11598-11602, issn 0027-8424Article

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cellsATKINS, M. B; MIER, J. W; PARKINSON, D. R et al.The New England journal of medicine. 1988, Vol 318, Num 24, pp 1557-1563, issn 0028-4793Article

A new american joint committee on cancer staging system for cutaneous melanomaBALCH, C. M; BUZAID, A. C; REINTGEN, D et al.Cancer. 2000, Vol 88, Num 6, pp 1484-1491, issn 0008-543XArticle

Liver metastases from melanoma : Detection with multiphasic contrast-enhanced CTBLAKE, S. P; WEISINGER, K; ATKINS, M. B et al.Radiology. 1999, Vol 213, Num 1, pp 92-96, issn 0033-8419Article

Immunotherapy and experimental approaches for metastatic melanomaATKINS, M. B.Hematology/oncology clinics of North America. 1998, Vol 12, Num 4, issn 0889-8588, viii,877-902 [27 p.]Article

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaHAWKINS, M. J; ATKINS, M. B; GAYNOR, E. R et al.Journal of immunotherapy. 1994, Vol 15, Num 1, pp 74-78, issn 1053-8550Article

Local excision of rectal carcinoma : early results with combined chemoradiation therapy using 5-fluorouracil and leucovorinGRAHAM, R. A; ATKINS, M. B; KARP, D. D et al.Diseases of the colon & rectum. 1994, Vol 37, Num 4, pp 308-312, issn 0012-3706Conference Paper

A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyTILG, H; PAPE, D; TREHU, E et al.Journal of immunological methods. 1993, Vol 163, Num 2, pp 253-258, issn 0022-1759Article

Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cellsMIER, J. W; DINARELLO, C. A; ATKINS, M. B et al.The Journal of immunology (1950). 1987, Vol 139, Num 4, pp 1268-1272, issn 0022-1767Article

The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)ALLEGRETTA, M; ATKINS, M. B; DEMPSEY, R. A et al.Journal of clinical immunology. 1986, Vol 6, Num 6, pp 481-490, issn 0271-9142Article

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma : Analysis of 270 patients treated between 1985 and 1993ATKINS, M. B; LOTZE, M. T; PARADISE, C et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2105-2116, issn 0732-183XArticle

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaDU BOIS, J. S; TREHU, E. G; ATKINS, M. B et al.Journal of clinical oncology. 1997, Vol 15, Num 3, pp 1052-1062, issn 0732-183XConference Paper

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; FISHER, R. I et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 1, pp 52-56, issn 1067-5582Article

Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancyMASSAROTTI, E. M; LIU, N. Y; MIER, J et al.The American journal of medicine. 1992, Vol 92, Num 6, pp 693-697, issn 0002-9343Article

Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-α therapy for metastatic carcinoma : a case reportSAUTER, N. P; ATKINS, M. B; MIER, J. W et al.The American journal of medicine. 1992, Vol 92, Num 4, pp 441-444, issn 0002-9343Article

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancyATKINS, M. B; VACHINO, G; TILG, H. J et al.Journal of clinical oncology. 1992, Vol 10, Num 11, pp 1802-1809, issn 0732-183XArticle

Interaction of an α-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastasesTATRO, J. B; WEN, Z; ENTWISTLE, M. L et al.Cancer research (Baltimore). 1992, Vol 52, Num 9, pp 2545-2548, issn 0008-5472Conference Paper

Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapyBERGSTROM, R. W; ATKINS, M. B; MIER, J. W et al.Journal of clinical & laboratory immunology. 1990, Vol 31, Num 4, pp 189-193, issn 0141-2760Article